Spots Global Cancer Trial Database for Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Official Title: A Phase 2 Study of BAY 43-9006 (IND 69896) in Chemosensitive Relapsed Aggressive Non-Hodgkin's Lymphomas
Study ID: NCT00278382
Study Description
Brief Summary: Sorafenib may stop the growth of cancer cells by blocking blood flow to the cancer and by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well sorafenib works in treating patients with chemosensitive recurrent aggressive non-Hodgkin's lymphoma
Detailed Description: PRIMARY OBJECTIVES: I. Determine the overall response rate, including complete and partial responses, in patients with chemosensitive, relapsed, aggressive, non-Hodgkin's lymphoma treated with sorafenib. SECONDARY OBJECTIVES: I. Determine progression-free and overall survival of patients treated with this drug. II. Determine response duration in patients treated with this drug. OUTLINE: This is an open-label study. Patients receive oral sorafenib twice daily in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Contact Details
Name: Meyer Heyman
Affiliation: University of Maryland Greenebaum Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
